Protein clues may predict chemo success in breast cancer
NCT ID NCT00911911
First seen Jun 26, 2026 · Last updated Sep 18, 2026 · Updated 3 times
Summary
This completed study looked at blood and tumor samples from 66 women with breast cancer who were about to receive chemotherapy before surgery. Researchers searched for unique protein patterns that might show whether the tumor would shrink with treatment. The goal was to find a way to personalize chemotherapy and avoid ineffective treatments.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict which breast cancer patients will respond well to chemotherapy before treatment starts.
- What could go wrong
- This is an observational study that only looks for protein patterns—it does not test a new treatment. The results may not lead to a practical test or change how patients are treated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
66 people
The number who actually took part.
- Started
-
Feb 2007
- Finished
-
Jan 2012
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Women aged more than 18 years * Histologically proven breast carcinoma * Neo-adjuvant chemotherapy with anthracyclines and/or taxanes * No prior chemotherapy * Written informed consent Exclusion Criteria: * Metastatic disease
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Henri Becquerel
Rouen, 76038, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Geroges PIANTA Hospital
Thonon-les-Bains, 74 203, France
-
Hopital Saint Vincent
Lille, 59020, France
-
Intercommunal Hospital
Annemasse, 74 107, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can a mindfulness program boost Self-Compassion in breast cancer survivors?
- Can a Decades-Old Anti-Inflammatory drug quiet the joint pain that drives women off breast cancer therapy?